Aimovig ™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention

Patients With Episodic Migraine Taking Aimovig Reported Significant and Meaningful Benefits Over Six Months, With Reduced Monthly Migraine Days and Acute Medication Use Fifty Percent of Patients Taking Aimovig 140 mg Had Their Migraine Days Cut by at Least Half - Nearly Three-Fold Higher Odds Compared to Placebo Patients Taking Aimovig Reported Reduced Physical Impairment and Improved Ability to Participate in Daily Activities Based on a Novel Patient-Reported Outcomes Tool Ninety Percent of Patients Completed the Six-Month Study; Data Reinforce the Safety and Tolerability Profile of Aimovig Consistently Seen in the Entire Clinical Program THOUSAND OAKS, Calif., Nov. 29, 2017 /PRN...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news